QTTB — Q32 Bio Inc

Q32 Bio Inc (QTTB) is a biotechnology company listed on NASDAQ. It is led by Jodie Pope Morrison, based in 830 Winter Street, Waltham, MA, United States, 02451, with about 28 employees. Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti"interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb " CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition. The company was founded in 2017 and is based in Waltham, Massachusetts.

Net income was -$7.4M. QTTB currently screens at market cap $32.4M.

Use this QTTB page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the QTTB quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the QTTB SEC filings page. Lician reads the product cache first so this HTML stays unique to Q32 Bio Inc even when a live quote feed is slow.